Page 14 - Dr Reddy’s Laboratories
Dr Reddy's falls 9% in two days on disappointing Q1 results
The stock dipped 6% to Rs 2,470, extending its previous day's 3% decline on BSE
 "Dr Reddy's falls 9% in two days on disappointing Q1 results")
Dr Reddy's out licenses phase-3 clinical trial drug to CHD Biosciences
The drug candidate is used for the prevention of surgical site infections
 "Dr Reddy's out licenses phase-3 clinical trial drug to CHD Biosciences")
USFDA observations 'unmistakably' beneficial in long run: Dr Reddy's
Dr Reddy's adds that these observations helped the company to accelerate pace of quality reforms
 "USFDA observations 'unmistakably' beneficial in long run: Dr Reddy's")
Dr Reddy's announces commercialisation of Vozet tablets in India
Vozet tablets are used for the treatment of allergic Rhinitis and chronic Urticaria
 "Dr Reddy's announces commercialisation of Vozet tablets in India")
Dr Reddy's gains on receiving EIR for Miryalaguda plant
The stock was up 3% to Rs 2,698 on BSE in intra-day trade.
Dr Reddy's SEZ unit completes USFDA inspection for second time
US drug regulator audited company's API manufacturing unit at the same plant in April
 "Dr Reddy's SEZ unit completes USFDA inspection for second time")
Dr Reddy's biosimilars capacity gets boost with GE Healthcare's FlexFactory
BS ReporterHyderabad, 19 MayDr Reddy's Laboratories (DRL) will install India's first single-use manufacturing platform to expand the biologics production capacity at its facility in Hyderabad. GE Healthcare's bio-manufacturing platform FlexFactory will help the Hyderabad-based drug major increase its capacity to meet both the expected growth of its currently marketed biosimilars as well as support the launch of new biosimilar products in the next few years. With this, the pharma company will boost its manufacturing capacity as the overall project set-up timeline for FlexFactory is typically 9 to 12 months. It will continue to grow patient access globally for biotech-based therapies.The new FlexFactory enables DRL's transition from stainless steel to single-use technologies that bring enhanced flexibility and efficiency into their manufacturing set-up. Single-use technologies facilitate multi-product manufacturing and improve productivity by increasing the number of lots manufactured. .
Dr Reddy's Q4 net profit rises 3-fold to Rs 337.6 cr
Shares of the company were trading 0.14% down at Rs 2,588.75 on BSE
Dr Reddy's hits 52-week low ahead of Q4 results
Since Feb 3, post Q3FY17 results, the stock declined 19% as compared to 7% rise in Sensex.
Dr Reddy's gains as USFDA completes inspection of Srikakulam SEZ unit
The stock was up 3% at Rs 2,712 against 0.18% decline in the S&P BSE Sensex at 09:30 am.
Dr Reddy's Srikakulam unit receives Form 483 with 2 observations
Srikakulam unit is among three facilities that received warning letter from US FDA in Nov 2015
Dr Reddy's unit fails to clear US FDA audit
The US drugs regulator had issued a warning letter to three of firm manufacturing facilities
No claims for monetary damages: Dr Reddy's on patent infringement
Claims sought injunctive relief to prohibit manufacturing, use, import, sale of palonosetron product prior to expiration
 "No claims for monetary damages: Dr Reddy's on patent infringement")
Dr Reddy's hits 52-week low on patent infringement
The stock hit a 52-week low of Rs 2,799, down 4% on the National Stock Exchange in intra-day trade.
Dr Reddy's launches generic drugs in France, to expand operations in Europe
The company recently launched select products of its hospital portfolio in Italy and Spain
Dr Reddy's Q3 net profit dips by 19% to Rs 470 cr
Revenues dropped by 7% to Rs 3,707 crore y-o-y
 "Dr Reddy's Q3 net profit dips by 19% to Rs 470 cr")
USFDA to re-inspect Dr Reddy's plants by March
The company received a warning letter from the USFDA on November 5, 2015, for specific violations
Dr Reddys Lab hits three-month high
In past three-trading sessions, post QFY17 results the stock gained 7% as compared to 1.62% decline in Sensex
 "Dr Reddys Lab hits three-month high")
Dr Reddy's announces collaboration with Gland Pharma for US market
Combined sale of branded and generic versions of the products in the US is approximately $1 billion
Dr Reddy's Q2 net down 60% at Rs 308 cr as US generic sales plunge
Declining US sales had a bearing on the company's revenues and profitability
 "Dr Reddy's Q2 net down 60% at Rs 308 cr as US generic sales plunge")